WO2008019061A3 - Anti-il-6 monoclonal antibodies and uses thereof - Google Patents

Anti-il-6 monoclonal antibodies and uses thereof Download PDF

Info

Publication number
WO2008019061A3
WO2008019061A3 PCT/US2007/017337 US2007017337W WO2008019061A3 WO 2008019061 A3 WO2008019061 A3 WO 2008019061A3 US 2007017337 W US2007017337 W US 2007017337W WO 2008019061 A3 WO2008019061 A3 WO 2008019061A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
amino acid
well
region selected
acid variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/017337
Other languages
French (fr)
Other versions
WO2008019061A2 (en
Inventor
Ernest S Smith
Wei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaccinex Inc
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR20097003512A priority Critical patent/KR101479537B1/en
Priority to EA200900037A priority patent/EA200900037A1/en
Priority to AU2007282023A priority patent/AU2007282023B2/en
Priority to EP07811042.6A priority patent/EP2064241B1/en
Priority to JP2009522880A priority patent/JP2009545319A/en
Priority to BRPI0715115-2A priority patent/BRPI0715115A2/en
Priority to CA2657763A priority patent/CA2657763C/en
Priority to CN2007800289537A priority patent/CN101563365B/en
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Priority to MX2009001110A priority patent/MX2009001110A/en
Publication of WO2008019061A2 publication Critical patent/WO2008019061A2/en
Publication of WO2008019061A3 publication Critical patent/WO2008019061A3/en
Priority to NO20090224A priority patent/NO20090224L/en
Priority to IL196550A priority patent/IL196550A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides novel monoclonal antibodies that bind specifically to IL- 6. The antibodies of the invention comprise a variable heavy chain (VH) region selected from any of the VH regions disclosed herein as well as amino acid variants thereof, and/or a variable light chain (VL) region selected from any of the VL regions disclosed herein as well as amino acid variants thereof. The invention also provides methods of treating diseases and disorders associated with IL-6 expression and/or activity.
PCT/US2007/017337 2006-08-03 2007-08-03 Anti-il-6 monoclonal antibodies and uses thereof Ceased WO2008019061A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2657763A CA2657763C (en) 2006-08-03 2007-08-03 Anti-il-6 monoclonal antibodies and uses thereof
AU2007282023A AU2007282023B2 (en) 2006-08-03 2007-08-03 Anti-IL-6 monoclonal antibodies and uses thereof
EP07811042.6A EP2064241B1 (en) 2006-08-03 2007-08-03 Anti-il-6 monoclonal antibodies and uses thereof
JP2009522880A JP2009545319A (en) 2006-08-03 2007-08-03 Anti-IL-6 monoclonal antibody and use thereof
BRPI0715115-2A BRPI0715115A2 (en) 2006-08-03 2007-08-03 isolated monoclonal antibody, isolated nucleic acid molecule, expression vector, host cell, methods for treating a disease, and for producing an isolated monoclonal antibody, use of isolated monoclonal antibody, and, pharmaceutical composition
CN2007800289537A CN101563365B (en) 2006-08-03 2007-08-03 Anti-IL-6 monoclonal antibodies and uses thereof
MX2009001110A MX2009001110A (en) 2006-08-03 2007-08-03 Anti-il-6 monoclonal antibodies and uses thereof.
KR20097003512A KR101479537B1 (en) 2006-08-03 2007-08-03 Anti-il-6 monoclonal antibodies and uses thereof
EA200900037A EA200900037A1 (en) 2006-08-03 2007-08-03 MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-6 (IL-6) AND THEIR APPLICATION
NO20090224A NO20090224L (en) 2006-08-03 2009-01-15 Anti-IL-6 Monoclonal Antibodies and Uses thereof
IL196550A IL196550A0 (en) 2006-08-03 2009-01-15 Anti-il-6 monoclonal antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83510706P 2006-08-03 2006-08-03
US60/835,107 2006-08-03

Publications (2)

Publication Number Publication Date
WO2008019061A2 WO2008019061A2 (en) 2008-02-14
WO2008019061A3 true WO2008019061A3 (en) 2008-10-09

Family

ID=39033490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/017337 Ceased WO2008019061A2 (en) 2006-08-03 2007-08-03 Anti-il-6 monoclonal antibodies and uses thereof

Country Status (17)

Country Link
US (1) US7919095B2 (en)
EP (1) EP2064241B1 (en)
JP (1) JP2009545319A (en)
KR (1) KR101479537B1 (en)
CN (1) CN101563365B (en)
AU (1) AU2007282023B2 (en)
BR (1) BRPI0715115A2 (en)
CA (1) CA2657763C (en)
CO (1) CO6150192A2 (en)
CR (1) CR10563A (en)
EA (1) EA200900037A1 (en)
IL (1) IL196550A0 (en)
MA (1) MA30653B1 (en)
MX (1) MX2009001110A (en)
NO (1) NO20090224L (en)
WO (1) WO2008019061A2 (en)
ZA (1) ZA200900514B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
JP2011520898A (en) 2008-05-13 2011-07-21 ノビミューン エスアー Anti-IL-6 / IL-6R antibodies and methods for their use
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
JP2012503490A (en) * 2008-09-26 2012-02-09 ワイス・エルエルシー Single chain antibody library design
KR20110094307A (en) * 2008-11-13 2011-08-23 펨타 파마슈티컬스, 인크. Humanized Anti-IL-6 Antibody
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
KR20110091780A (en) 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 IL-6 antagonists to prevent or treat cachexia, weakness, fatigue and / or fever
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc Antagonists of il-6 to prevent or treat thrombosis
LT2544719T (en) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37-binding molecules and immunoconjugates thereof
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
US20120189621A1 (en) 2011-01-21 2012-07-26 Yann Dean Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
AU2012236210B2 (en) 2011-04-01 2016-02-04 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2014066167A1 (en) * 2012-10-22 2014-05-01 Fountain Biopharma Inc. Antibodies to interleukin-6 and uses thereof
KR102149206B1 (en) * 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. Il-6 antagonists and uses thereof
BR112017026027A2 (en) 2015-06-08 2018-08-14 Debiopharm Int Sa anti-cd37 immunoconjugate and anti-cd20 antibody combinations
AU2016302768B2 (en) 2015-07-31 2019-08-22 Medimmune Limited Methods for treating hepcidin-mediated disorders
JP6890581B2 (en) 2015-08-28 2021-06-18 デビオファーム インターナショナル， エス． アー． Antibodies and assays for the detection of CD37
CN109310755A (en) * 2016-02-02 2019-02-05 卡德门企业有限公司 The bispecific binding protein of PD-L1 and KDR
US20190192692A1 (en) * 2016-05-05 2019-06-27 The Trustees Of The University Of Pennsylvania DNA Monoclonal Antibodies Targeting IL-6 and CD126
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
JP7630906B2 (en) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー Treatment of diuretic resistance
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
AU2019277836A1 (en) 2018-05-30 2021-01-21 Debiopharm International, S.A. Anti-CD37 immunoconjugate dosing regimens
CN109517064B (en) * 2018-10-10 2020-05-08 北京汇智和源生物技术有限公司 Humanized monoclonal antibody of interleukin-6, coding gene and application thereof
CN114375205A (en) 2019-06-20 2022-04-19 武田药品工业株式会社 Approaches to treatment with virus-based gene therapy
CN112279913B (en) * 2020-10-30 2022-05-03 上海百英生物科技有限公司 Anti-human IL-6 monoclonal antibody and application
WO2022115705A2 (en) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
CN113980129B (en) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 Group of IL-11 monoclonal antibodies and medical application thereof
CN115925792B (en) * 2022-08-19 2025-06-27 浙江农林大学 Torreya grandis active peptide and its application in preparing blood pressure lowering product

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312996A2 (en) * 1987-10-19 1989-04-26 Kishimoto, Tadamitsu, Prof. Anti-human bcdf monoclonal antibody
EP0399429A1 (en) * 1989-05-22 1990-11-28 Toray Industries, Inc. Anti-human interleukin-6 monoclonal antibody
EP0410813A1 (en) * 1989-07-28 1991-01-30 Fujirebio Inc. Anti-human BCDF monoclonal antibody and immunoassay using the same
DE3939706C1 (en) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
US5856135A (en) * 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
WO2004039826A1 (en) * 2001-11-14 2004-05-13 Centocor, Inc. Anti-il-6 antibodies, compositions, methods and uses
EP1536012A1 (en) * 2002-08-30 2005-06-01 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88375A (en) * 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies specifically binding to natural and recombinant interferon-beta2 and method of purification of said interferon-beta2
FI903489A7 (en) * 1988-11-11 1990-07-10 Medical Res Council Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors
JPH03139292A (en) * 1989-05-22 1991-06-13 Toray Ind Inc Monoclonal antibody against human interleukin 6
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
JP3614183B2 (en) * 1993-05-31 2005-01-26 中外製薬株式会社 Reconstituted human antibody against human interleukin-6
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
DE69534075T2 (en) * 1994-06-07 2005-07-21 Chugai Seiyaku K.K. PREVENTIVE AND CLEANING AGENTS FOR DISEASES CAUSED BY FIBRIN OR THROMBUS TRAINING
AU700819B2 (en) 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
US6086874A (en) * 1994-12-29 2000-07-11 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
AU736282B2 (en) * 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
ATE383875T1 (en) 1998-03-17 2008-02-15 Chugai Pharmaceutical Co Ltd PROPHYLACTIC OR THERAPEUTIC AGENTS AGAINST INFLAMMATORY DISEASES OF THE DIGESTIVE TRACT CONTAINING ANTAGONISTIC IL-6 RECEPTOR ANTIBODIES
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
CA2341239C (en) 1998-08-24 2011-01-04 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
JP2003525862A (en) * 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ Inhibition of STAT3 signaling for treatment of human cancer
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
CA2407292A1 (en) * 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
AU1095202A (en) * 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
JP4889187B2 (en) * 2000-10-27 2012-03-07 中外製薬株式会社 A blood MMP-3 concentration reducing agent comprising an IL-6 antagonist as an active ingredient
CN1306272C (en) * 2000-11-17 2007-03-21 罗切斯特大学 Method of screening for encoding antigen-specific immunoglobulin molecules or antigen-specific fragments thereof
US20030044406A1 (en) * 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
NZ528076A (en) * 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
JP4323317B2 (en) * 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） Methods for cloning variable region sequences
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
CA2506230A1 (en) 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
AU2004210626A1 (en) * 2003-02-04 2004-08-26 Centocor Inc. Use of IL-6 antagonists in combination with steroids to enhance apoptosis
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1607100A4 (en) * 2003-02-24 2007-06-13 Chugai Pharmaceutical Co Ltd CURATIVE TREATMENT FOR MEDICAL INJURIES CONTAINING AN INTERLEUKIN-6 ANTAGONIST
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005023193A2 (en) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methods of treating endometriosis
JP2007526022A (en) * 2003-10-24 2007-09-13 メドトロニック・インコーポレーテッド Techniques for treating neurological disorders by diminishing the production of pro-inflammatory mediators
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
CA2555688C (en) 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
EP1828250A2 (en) 2004-12-16 2007-09-05 Genentech, Inc. Methods for treating autoimmune disorders
US20060228416A1 (en) * 2005-04-06 2006-10-12 Marie-Pierre Faure Methods for modulating topical inflammatory response
EP1712241A1 (en) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
PA8672101A1 (en) * 2005-04-29 2006-12-07 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312996A2 (en) * 1987-10-19 1989-04-26 Kishimoto, Tadamitsu, Prof. Anti-human bcdf monoclonal antibody
EP0399429A1 (en) * 1989-05-22 1990-11-28 Toray Industries, Inc. Anti-human interleukin-6 monoclonal antibody
EP0410813A1 (en) * 1989-07-28 1991-01-30 Fujirebio Inc. Anti-human BCDF monoclonal antibody and immunoassay using the same
DE3939706C1 (en) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
US5856135A (en) * 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2004039826A1 (en) * 2001-11-14 2004-05-13 Centocor, Inc. Anti-il-6 antibodies, compositions, methods and uses
EP1536012A1 (en) * 2002-08-30 2005-06-01 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHIMAMURA T ET AL: "ANALYSIS OF INTERLEUKIN 6 (IL-6)/IL-6 RECEPTOR SYSTEM USING MONOCLONAL ANTI-IL-6 ANTIBODIES", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 28, no. 11, 1 November 1991 (1991-11-01), pages 1155 - 1161, XP000764448, ISSN: 0161-5890 *
WIJDENES J ET AL: "Human recombinant dimeric il-6 binds to its receptor as detected by anti-il-6 monoclonal antibodies", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 28, no. 11, 1 January 1991 (1991-01-01), pages 1183 - 1192, XP002974189, ISSN: 0161-5890 *

Also Published As

Publication number Publication date
US7919095B2 (en) 2011-04-05
JP2009545319A (en) 2009-12-24
KR20090039801A (en) 2009-04-22
NO20090224L (en) 2009-03-31
KR101479537B1 (en) 2015-01-07
WO2008019061A2 (en) 2008-02-14
CR10563A (en) 2009-04-14
CN101563365A (en) 2009-10-21
ZA200900514B (en) 2010-04-28
AU2007282023B2 (en) 2012-09-13
EA200900037A1 (en) 2009-10-30
MX2009001110A (en) 2009-05-11
MA30653B1 (en) 2009-08-03
US20080075726A1 (en) 2008-03-27
CN101563365B (en) 2012-10-31
EP2064241A2 (en) 2009-06-03
EP2064241B1 (en) 2015-10-07
AU2007282023A1 (en) 2008-02-14
IL196550A0 (en) 2011-08-01
BRPI0715115A2 (en) 2013-06-04
CA2657763C (en) 2016-05-31
CA2657763A1 (en) 2008-02-14
CO6150192A2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
MX2009001110A (en) Anti-il-6 monoclonal antibodies and uses thereof.
WO2008079246A3 (en) Cd44 antibodies
WO2007024846A3 (en) Anit-il-23 antibiodies
WO2006114704A3 (en) P-cadherin antibodies
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
MY159201A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
TW200722518A (en) Sc(fv)2 structural isomers
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2007113172A3 (en) Antibodies against amyloid-beta peptide
NZ595235A (en) Compositions and methods for increasing muscle growth
WO2010021697A3 (en) Antibodies to ccr2
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2007058823A3 (en) Anti-egfr antibodies
UA95478C2 (en) Humanized c-kit antibody
GEP20104887B (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2007143168A3 (en) High affinity antibodies to human il-6 receptor
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
WO2009048537A3 (en) Humanized antibody
NZ594682A (en) Fully human antibodies specific to cadm1
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
WO2007068750A3 (en) Immunoglobulins directed against nogo
WO2007003421A3 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780028953.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2657763

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009522880

Country of ref document: JP

Ref document number: CR2009-010563

Country of ref document: CR

WWW Wipo information: withdrawn in national office

Ref document number: CR2009-010563

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2007282023

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200900037

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 574282

Country of ref document: NZ

Ref document number: 272/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009010128

Country of ref document: EG

Ref document number: 09007783

Country of ref document: CO

Ref document number: MX/A/2009/001110

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12009500227

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007282023

Country of ref document: AU

Date of ref document: 20070803

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097003512

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: DZP2009000114

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007811042

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWP Wipo information: published in national office

Ref document number: CR2009-010563

Country of ref document: CR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811042

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0715115

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090129